These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Surveillance of patients to detect recurrent thyroid carcinoma. Grigsby PW; Baglan K; Siegel BA Cancer; 1999 Feb; 85(4):945-51. PubMed ID: 10091774 [TBL] [Abstract][Full Text] [Related]
8. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871 [TBL] [Abstract][Full Text] [Related]
9. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. Spanu A; Solinas ME; Chessa F; Sanna D; Nuvoli S; Madeddu G J Nucl Med; 2009 Feb; 50(2):184-90. PubMed ID: 19164225 [TBL] [Abstract][Full Text] [Related]
10. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. Martins RG; Caplan RH; Lambert PJ; Rooney B; Kisken WA J Am Coll Surg; 1997 Oct; 185(4):388-97. PubMed ID: 9328388 [TBL] [Abstract][Full Text] [Related]
11. Radio-guided surgery for persistent differentiated papillary thyroid cancer: case presentations and review of the literature. Negele T; Meisetschläger G; Brückner T; Scheidhauer K; Schwaiger M; Vogelsang H Langenbecks Arch Surg; 2006 Jun; 391(3):178-86. PubMed ID: 16491404 [TBL] [Abstract][Full Text] [Related]
12. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995 [TBL] [Abstract][Full Text] [Related]
13. [Intraoperative localization measurement following preoperative radioiodine marking to facilitate the treatment of differentiated thyroid carcinoma]. Littmann K; Magdsick G; Strötges MW; Eigler FW Chirurg; 1980 Jun; 51(6):389-94. PubMed ID: 7449540 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514 [TBL] [Abstract][Full Text] [Related]
15. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706 [TBL] [Abstract][Full Text] [Related]
16. Completion thyroidectomy of well-differentiated thyroid cancer - a prospective, randomised study. Proczko M; Stefaniak T; Sworczak K; Kobiela J; Lachiński AJ; Stepaniak P; Sledziński Z Endokrynol Pol; 2013; 64(5):335-9. PubMed ID: 24186588 [TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195 [TBL] [Abstract][Full Text] [Related]
18. [Outcome in cervical recurrences of papillary or follicular thyroid cancer]. Mirallié E; Hamy A; Floch I; Sagan C; Paineau J; Murat A; Le Néel JC; Visset J Ann Chir; 1999; 53(7):577-82. PubMed ID: 10520496 [TBL] [Abstract][Full Text] [Related]